Hepatology International最新文献

{"title":"Comment on \"Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study\".","authors":"Huikang Wang, Xinjun Xu, Xicheng Song, Yu Zhang","doi":"10.1007/s12072-025-10970-9","DOIUrl":"10.1007/s12072-025-10970-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1193-1195"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letters to editor \"Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial\" and \"Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy\".","authors":"Di Wu, Da Huang, Weiming Yan, Qin Ning","doi":"10.1007/s12072-026-11055-x","DOIUrl":"10.1007/s12072-026-11055-x","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1259-1260"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma.","authors":"Li Zhang, Maopei Chen, Jing Sun, Zhaochong Zeng, Yang Zhang, Ping Yang, Yixing Chen, Shisuo Du","doi":"10.1007/s12072-026-11109-0","DOIUrl":"10.1007/s12072-026-11109-0","url":null,"abstract":"<p><strong>Background and aims: </strong>This study aimed to investigate the efficacy of radiation therapy and targeted therapy combined with or without immunotherapy for hepatocellular carcinoma (HCC) patients with lymph node metastases (LNM).</p><p><strong>Methods: </strong>A total of 132 HCC patients with LNM were enrolled in this study. Propensity score matching (PSM) and stabilized inverse probability of treatment weighting (sIPTW) were used to balance baseline variables between groups. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and clinical safety were compared between the two treatment arms.</p><p><strong>Results: </strong>There were 61 patients in radiotherapy plus targeted therapy (RT) group, and 71 patients in radiation therapy, targeted therapy combined with immunotherapy (RTI) group. In the overall cohort, the median OS was 12.8 months in the RT group and 18.8 months in the RTI group (p = 0.003). Multivariate analysis identified that tumor thrombus status, distant metastasis, lymph node (LN) number, LN size and immunotherapy were independent prognostic factors for survival. Median PFS was 7.0 months in the RT group and 11.9 months in the RTI group (p = 0.001). The ORRs were 70.5% for the RT group and 85.9% for the RTI group in the total cohort (p = 0.031). After PSM and IPTW adjustment, ORR remained significantly higher in the RTI group (PSM: 88.9% vs. 68.9%, p = 0.020; IPTW: 86.8% vs. 71.5%, p = 0.033). The incidence of treatment-related adverse events was similar in both groups.</p><p><strong>Conclusions: </strong>The findings of this study suggest that RTI provides superior treatment responses and survival outcomes compared to RT in HCC patients with LNM, while maintaining a comparable safety profile.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1177-1192"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study.","authors":"Wen Wang, Jiajia Mai, Jinlin Hou, Zhongyuan Xu, Xian Yu, Hong Ren, Xieer Liang, Yi Yang, Zhihong Liu, Hong Zhang, Shan Zhong, Yilei Wen, Tingting Lu, Haixia Cao, Xiao Qiu, Lidan Wang, Di Zhao, Miao Wang, Chengyong Yang, Guofeng Cheng, Junqi Niu, Yanhua Ding","doi":"10.1007/s12072-026-11102-7","DOIUrl":"10.1007/s12072-026-11102-7","url":null,"abstract":"<p><strong>Background/purpose: </strong>AHB-137 is a novel antisense oligonucleotide targeting a conserved 3'-terminal region of HBV mRNA. This phase 1a/1b study evaluated the safety, pharmacokinetics (PK), and antiviral activity of AHB-137 in Chinese healthy volunteers (HVs) and chronic hepatitis B (CHB) patients.</p><p><strong>Methods: </strong>In Phase 1a, 52 HVs received single ascending doses (75-450 mg) or multiple ascending doses (MAD; 150 or 300 mg) of AHB-137 or placebo. In Phase 1b, 20 HBeAg-negative, nucleos(t)ide analogue (NA)-suppressed CHB patients with baseline HBsAg 100-1000 IU/mL received MAD AHB-137 (150 or 300 mg) or placebo (8:2), and 2 patients with baseline HBsAg 1000-3000 IU/mL received open-label AHB-137 300 mg. MAD comprised 6 subcutaneous doses over 4 weeks including loading doses on Days 4 and 11, with safety, PK and virologic follow-up assessments.</p><p><strong>Results: </strong>No serious adverse events, deaths or discontinuations occurred. Most treatment-related adverse events were Grade 1-2, including injection site reactions, pyrexia, and asymptomatic lab abnormalities. Transaminase elevations were self-limiting; one Grade 3 ALT elevation in the 300 mg CHB cohort coincided with rapid HBsAg loss. PK showed rapid absorption (T_max 3-5 h), dose-proportionality, and a terminal half-life of 128-195 h without meaningful accumulation. In CHB patients, 4 weeks of AHB-137 induced dose-dependent HBsAg reductions (mean maximum - 1.1 vs. - 2.1 log₁₀ IU/mL at 150 vs. 300 mg), 50.0% of the 300 mg cohort achieved ≥ 2 log₁₀ IU/mL reduction. Preliminary HBsAg loss was observed in a small subset of patients during follow-up.</p><p><strong>Conclusion: </strong>AHB-137 demonstrated favorable safety, predictable PK, and dose-dependent HBsAg reductions, including HBsAg loss, supporting its further development for CHB functional cure.</p><p><strong>Registration number: </strong>ClinicalTrials.gov. number: NCT06115993. Chinadrugtrials.org.cn. number: CTR20232098.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1035-1046"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148005167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The neglected comorbidity: why pancreatic function can no longer be overlooked in alcohol-related ACLF research.","authors":"Lei Wang, Hao Tan, Haitao Zhang, Jiacheng Gao, Xiaofeng Luan, Hangyu Liu","doi":"10.1007/s12072-025-10983-4","DOIUrl":"10.1007/s12072-025-10983-4","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1217-1218"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-step paradigms for Hepatitis B functional cure: insights from the anchor combination therapy trial.","authors":"Ze Bo, Jing Yang, Zheng Zhang, Jianbo Wu","doi":"10.1007/s12072-025-11012-0","DOIUrl":"10.1007/s12072-025-11012-0","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1253-1254"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting diabetes and mortality in ALD-ACLF: methodological and clinical considerations.","authors":"Yu Huang, Lingfeng Tang, Hao Liu","doi":"10.1007/s12072-025-10987-0","DOIUrl":"10.1007/s12072-025-10987-0","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1219-1220"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards precise evaluation of steatotic liver disease subtypes and adverse pregnancy outcomes: methodological insights.","authors":"Pengtao Hu, Jian Lu, Chengyu Lv","doi":"10.1007/s12072-025-10994-1","DOIUrl":"10.1007/s12072-025-10994-1","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1242-1243"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure\".","authors":"Shyam Sundar Sah, Abhishek Kumbhalwar","doi":"10.1007/s12072-025-10975-4","DOIUrl":"10.1007/s12072-025-10975-4","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1209-1210"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study\".","authors":"Bin Cao, Zhenxing Deng, Ming Ouyang","doi":"10.1007/s12072-025-10969-2","DOIUrl":"10.1007/s12072-025-10969-2","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1237-1238"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145549037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}